選択的な心拍数減速による心不全の効果
Nikhil Pal1, Nadiya Sivaswamy1, Masliza Mahmod1
1From Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK (N.P., M.M., A.Y., J.M.F., J.S.D., H.W., S.N., H.A.); School of Medicine and Dentistry, University of Aberdeen, UK (N.S., A.R., S.S., D.K.D.); and Norwich Medical School, University of East Anglia, UK (M.F.).
Circulation
|September 5, 2015
まとめ
イバブラジンによる心拍の低下は,保存されたエジェクション分数 (HFpEF) の心不全患者の運動能力を改善しませんでした. この研究では,HFpEFの症状管理におけるイバブラディンの効果が疑問視されています.
科学分野:
- 心臓病科
- 臨床試験
- 薬理学について
背景:
- 保存されたエジェクション分数 (HFpEF) の心不全は,著しい罹病率と死亡率を示しています.
- 現在のHFpEF療法は限られており,新しい戦略の調査を促しています.
- イバブラジンによる心拍数低下は,潜在的な治療法として検討された.
研究 の 目的:
- HFpEF患者の運動能力を改善するという仮説を検証する.
- HFpEFにおけるイバブラディンの運動耐性を高める効果を評価する.
主な方法:
- ランダム化クロスオーバー研究が実施された.
- 症状のある運動制限のHFpEF患者22人を,それぞれ2週間のイバブラジンまたはプラセボにランダムに割り当てました.
- 酸素消費のピーク (o2ピーク) が主評価点であり,エコーカルディオグラフィとバイオマーカーの評価を含む二次評価点であった.
主要な成果:
- イバブラディンはHFpEFと高血圧群の両方でピーク心拍数を有意に低下させた.
- しかし,イバブラディンはHFpEFコホートにおけるO2ピークの変化を著しく悪化させた.
- E/ e' または脳ナトリウレチンペプチド濃度などの二次評価結果において,有意な改善は認められなかった.
結論:
- イバブラジンによる心拍の低下は,HFpEF患者における運動能力の改善にはなりません.
- これらの発見は,この集団における症状管理のためのイバブラディンの治療的価値に疑問を投げかけます.
関連する概念動画
01:30Heart Failure V: Medical Management
546
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
546
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:22Heart Failure Drugs: β-Blockers
1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
01:17Pathophysiology of Heart Failure
4.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K
01:29Heart Failure II: Pathophysiology
1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
603
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
603